Bexobrutideg earns FDA Orphan Drug status in Waldenström macroglobulinemia
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to bexobrutideg (NX-5948), a first-in-class Bruton’s tyrosine kinase (BTK) degrader, for
Lymphoma
Indolent B-Cell Lymphomas
News
News
Society Updates
SOHO launches new fundraising initiative
SOHO is launching a special initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September 3 and 6, 2025!
Multiple Myeloma
China NMPA approves IND for KPG-818 in relapsed or refractory MM
The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.
Lymphoma
T-Cell Lymphoma
FDA clears linperlisib for phase 3 trial in relapsed/refractory PTCL
The US Food and Drug Administration (FDA) has approved the design of a global phase 3 trial for linperlisib for the treatment of
Acute Lymphoblastic Leukemia
News
Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study
A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete responses (CRs) in
Society Updates
Ask the lymphoma expert: Dr. Maddocks
Have a burning question about a patient with B-cell malignancies for Hodgkin or non-Hodgkin lymphoma? Ask Kami Maddocks, MD, professor in the College
Cellular Therapy
Lymphoma
News
Risk factors for manufacturing failure, associated outcomes in patients receiving CAR-T for LBCL
Researchers found that prior use of bendamustine within six months of apheresis was the only baseline variable associated with a risk of manufacturing
Cellular Therapy
Multiple Myeloma
Patient case highlights secondary tumor after CAR-T treatment for myeloma
A case study of a 63-year-old male with early relapse of multiple myeloma (MM) indicated that treatment with a chimeric antigen receptor (CAR)
Leukemia
Lymphoma
Long-term use of TNF inhibitors for psoriasis may increase risk for certain blood cancers
A study assessed the risk of cancer in patients receiving long-term treatment with tumor necrosis factor (TNF)-alpha inhibitors and found that cumulative use
Multiple Myeloma
Combination monoclonal antibody treatment induces responses but also infections in MM
In a phase 1b/2 study, researchers assessed the feasibility of combining talquetamab and teclistamab for the treatment of relapsed or refractory multiple myeloma